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                                                INTRODUCTION
               Heart failure is the end stage of all diseases of the heart and is a
major cause of morbidity and mortality. Since 1970s the treatment of CHF`has been 
transformed,  resulting  in  major  benefit  to  patients.  This  advance  has  been  the 
consequence  of  better  understanding  of  the  pathophysiology,  investigations,  the 
introduction of  newer drugs and cardiac transplantation.  The traditional  treatment  of 
heart failure with digoxin and diuretics has been replaced by diuretics, ACE inhibitors 
and drugs directed against the origins of heart failure such as aspirin and lipid lowering 
drugs. Newer objectives are optimization of the quality of life, avoidance of hospital 
admissions prevention of progression of damage to the myocardium and prolongation of 
life.
             So it becomes important to conduct clinical and Para clinical studies to know 
about  the status,  precipitating factors  and complications of  the disease.  Only with a 
reliable  study,  changes  in  the  modality  of  approach  in  controlling,  diagnosing  and 
treating the disease can be done. Here, an attempt has been made to study on selected 
aspects of congestive heart failure.
                                           REVIEW OF LITERATURE
History:
 Heart failure, angina and the pulse were known in the ancient 
Egyptian  and  early  Greek  civilizations.  (Dallas  1993,  Horine  1941).  Hippocrates 
described cardiac cachexia, most vividly reports of the benefits of foxglove exists in 
Roman literature. (Moore, 1985)  Hering used nitrate in 1853 to treat heart failure, the 
first use of vasodilator. Bruton later in 1867 described the use of amyl nitrate to treat 
angina. ACE inhibitors were shown to be of benefit in terms of mortality in patients with 
heart failure for the first time in 1987. The large trail of digoxin, showing no effect on 
overall mortality, was reported in 1996.
Definitions of heart failure
1. A pathophysiological state in which an abnormality of cardiac    function   is 
responsible for the failure of the heart to pump blood at a rate commensurate with 
the requirements of the metabolizing tissues (Braunwald 1994). 
2.  Congestive heart failure represents a complex clinical syndrome,
     characterized by abnormalities of left ventricular function and 
     neurohormonal regulation, which are accompanied by effort 
     intolerance, fluid retention and reduced longevity.(Packer 1988).
3.  Symptoms  of  heart  failure,  objective  evidence  of  cardiac  dysfunction    and 
response  to  treatment  directed  towards  the  heart  failure.  (Task   force  of  the 
European society of cardiology 1995)
EPIDEMIOLOGY:
            Heart failure is a relatively common disorder. It is estimated that 4.6 million 
persons in the United States are being treated for heart failure, with 550,000 new cases 
diagnosed each year. (Dallas 1999, Massie - 1977)
             The prevalence of heart failure increases dramatically with age, 
occurring in 1 to 2 percent of persons aged 50 to 59 and up to 10 percent of individuals 
older than the age of 75. (Ho et al 1993)    
              Approximately 80 percent of all heart failure admissions occur in 
patients older than 65, as a result,  heart failure is the leading discharge diagnosis in 
persons 65 years or older in the United States (Rich 1999).
         Despite a steady decline in the incidence of coronary artery disease and stroke, 
both the incidence and prevalence of  heart failure continue to rise.
         Between 1985 and 1995 the number of heart failure hospitalizations 
increased by 5 percent and 8, 70,000 hospital discharges for heart failure 
occurred in 1996. (Haldeman – 1999) 
         In the United States approximately 45,000 deaths each year are
primarily caused by heart failure and heart failure is listed as a contributing cause in 
260,000 deaths (Dallas 1999).
         In smaller mid western areas, recent assessment has suggested a 
prevalence as high as 6% of population. The same prevalence of 6-7% also has been 
observed in Urban population. (Senni et al - 1999)
        The overall prevalence of heart failure is 3-20 per 1000 population
although this exceeds 100 per 1000 in those aged 65 yrs and over. The 
annual incidence of  heart failure is 1-5 per 1000 and the relative incidence doubles for 
each decade of life after  the age of 45 yrs. (Davis Hobbs, Lip – 2003). The overall 
incidence is likely to increase in the future because of  both an aging population and 
therapeutic  advances  in  the  management  of  acute  myocardial  infarction  leading  to 
improved survival in patients with impaired cardiac function. (Cowie et al - 1999).
                Three major factors such as age, race and gender influence the 
prevalence and outcome in patients with heart failure.
Age:
           The most important factor is age. The prevalence of CHF is less than 1% in 
patients < 50 yrs of age regardless of gender. At older than 50 years of age however, the 
prevalence increases to approximately 5% for patients  between 50 and 70 years of age, 
nearly 10% for all patients over 70 yrs of age and perhaps as high as 15% for patients 
over the age of 80.
          The impact of age alone leads to a significant continued increase in the prevalence 
of heart failure as recent statistics have suggested that there will be near doubling of 
patients over 65 years of age by the year 2030. (Dallas 2001).
Race:
          The second major influencing factor is race. There has been a higher prevalence of 
heart failure in blacks compares to whites.
          More importantly black patients develop heart failure at a younger age than white  
patients. (Bourassa et al 1993).
Gender: 
           The third major factor influencing the heart failure is gender. The 
national heart and nutrition education survey (NHANES) from 1988-1994 
estimated that there is an increased prevalence of congestive heart failure in men aged 
70  years  and  younger.  In  contrast,  women aged  older  than  70  years  have  a  higher 
prevalence.  This  difference  may  be  in  part  owing  to  the  increased  average  life 
expectancy in women (Anderson 2001). 
The highest prevalence of CHF is in black men followed by black women.
           Data derived from the National centre of Health Statistics report 
that total life expectancy for the United States Population is 76.7 years, Life expectancy 
is 73.8 years for men and 79.5 years for Women (2000 estimate). 
  While the overall incidence of congestive heart failure is probably equal between 
the two genders there are several unique features that may influence the prevalence of 
congestive heart failure in women, including a higher average ejection fraction for an 
equivalent  amount  of  symptoms  than  men  at  all  ages.  This  may  reflect  a  higher 
prevalence of primary diastolic rather than systolic dysfunction. (Gheorghide, Bonow 
1998)
          The Framingham data shows an age adjusted annual incidence of heart failure of 
0.14% in women and 0.23% in men. Survival in women is 
generally better than in men.
AETIOLOGY:
 The relative importance of aetiological factors in heart failure is 
dependent on the nature of the population being studied, as coronary artery disease and 
hypertension are common causes of heart failure in western countries, whereas valvular 
heart  diseases  and  nutritional  cardiac  diseases  are  more  common  in  the  developing 
world. (Zannad - 1999) 
The common causes of heart failure include:
1. coronary artery disease, Ischemia  
2. hypertension
3. cardiomyopathies
4. valvular heart disease and congenital heart diseases
5. arrhythmias
6. alcohol and drugs
- alcohol
- cardiac  depressant drugs (beta blockers and calcium                             
                            channel blockers)
7. high output failure
                          -    anemia, thyrotoxicosis, beriberi, etc           
8. pericardial diseases
9. primary right heart failure
-Pulmonary hypertension eg. pulmonary embolism, corpulmonale
                 -tricuspid incompetence
Coronary artery disease and its risk factors:     
            Coronary artery disease is the commonest cause of heart failure. In the studies of 
left ventricular dysfunction (SOL VD) Coronary artery disease accounted for about 75% 
of the cases of chronic heart failure.
(Khadra Saleem, Rand 1998)
            Coronary artery disease and hypertension (either alone or in the combination)  
were implicated as the cause in over 70% of cases of heart failure in the fragmentation 
study. (Ho – 1993)            
                 Coronary risk factors, such as smoking and diabetes are also 
risk markers for the development of heart failure. Smoking is an independent and strong 
risk factor for the development of heart failure in men, although the findings in women 
are less consistent.
             In Framingham heart study, diabetes and left ventricular 
hypertrophy were the most significant risk markers for the development of heart failure. 
Body weight and high ratio of total cholesterol concentration to high density lipoprotein 
cholesterol concentration are also independent risk factors for heart failure. Clearly these 
risk factors may increase the risk of heart failure through their effects on coronary artery 
disease, although diabetes alone may induce important structural and functional changes 
in the myocardium, which further increase the risk of heart failure.
 Hypertension:
            Hypertension has been associated with an increased risk of heart 
failure in several epidemiological studies. In the Framingham heart study, 
hypertension was reported as the cause of heart failure either alone or in 
association with other factors, in over 70% of cases on the basis of non 
invasive assessment. (Ho - 1993). However hypertension is probably a more common 
cause  of  heart  failure  in  selected  patient  groups,  including  females  and  black 
populations. Hypertension predisposes to the development of heart failure via a number 
of pathological mechanisms, including left ventricular hypertrophy. 
          Left ventricular hypertrophy is associated with left  ventricular systolic and 
diastolic dysfunction and an increased risk of myocardial infarction and it predisposes to 
both atrial and ventricular arrhythmias. Electrocardiographic left ventricular hypertrophy 
is strongly correlated with the development of heart failure, as it associated with a 14 
fold increase in the risk of heart failure in those aged 65 years or under.
Valvular heart disease:
         Rheumatic heart disease may have declined in certain parts of the 
world, but it still remains an important cause of heart failure in India and 
other  developing  nations.  In  the  Framingham  heart  study,  rheumatic  heart  disease 
accounted for heart failure in 2% of men and 3% of women, 
although the overall incidence of valvular heart disease has been steadily 
decreasing in the Framingham cohort over the past 30 years (HO - 1993).
         MR and AS are the most common causes of heart failure, secondary to valvular 
disease.  MR and  AR lead  to  volume overload,  in  contrast  with  AS which  leads  to 
pressure overload. The progression of heart failure in patients with valvular heart disease 
is dependent on the nature and extent of the valvular disease. In aortic stenosis heart 
failure develops at a relatively late stage and without, valve replacement, it is associated 
with a poor prognosis. In contrast, patients with chronic mitral or aortic regurgitation 
generally decline in a slower and more progressive manner. (Teerlink, et al 1991).
Cardiomyopathies:
        Cardiomyopathies are defined as the disease of the heart muscle that are not 
secondary to coronary heart disease, hypertension or others. As primary disease of heart 
muscle, cardiomyopathies are less common causes of heart failure, but awareness of 
their existence is necessary to make a diagnosis. Cardiomyopathies are separated into 
four  functional  categories  dilated,  hypertrophic,  restrictive  and  obliterative.  These 
groups  can  include  rare  specific  heart  muscle  diseases  such  as  hemochromatosis  in 
which  cardiac  involvement  occurs  as  part  of  a  systemic  disorder.  Dilated 
cardiomyopathy  is  a  more  common  cause  of  heart  failure  than  hypertrophic  and 
restrictive  Cardiomyopathies,  obliterative  cardiomypathy  is  essentially  limited  to 
developing countries. (Oakley 1997).
Arrhythmias:
          Cardiac  arrhythmias  are  more  common in patients  with  heart  failure  and 
associated structural heart diseases, including hypertensive patients with left ventricular 
hypertrophy.
          In the Hillingdon heart failure study 30% of patients presented for the first time 
with heart failure had atrial fibrillation and over 60% of patients admitted urgently with 
atrial fibrillation to a Glasgow hospital had echocardiographic evidence of impaired left 
ventricular function (Stevenson, 1995).
Alcohol and drugs:
          Alcohol has a direct toxic effect on the heart which may lead to acute heart failure  
or  heart  failure  as  a  result  of  arrhythmias,  commonly  atrial  fibrillation.  Excessive 
chronic alcohol consumption also leads to dilated cardiomyopathy.
          Alcohol is the identifiable cause of heart failure in 2-3% of cases. 
Chemotherapeutic agents (doxorubicin) and antiviral drugs (zidovudine) 
have been implicated in heart failure, through direct toxic effects on the 
myocardium. (Maki et al - 1998)
Endocrine causes:
          High output heart  failure is most  often seen in patients with anaemia and 
thyrotoxicosis.  Myxedema may present  with heart  failure  as  a  result  of   myocardial 
involvement of secondary to pericardial effusion.
Corpulmonale:
           Corpulmonale is defined as enlargement of the right ventricle 
secondary to abnormalities of the lungs, thorax, pulmonary ventilation or 
circulation.  It  sometimes  leads  to  right  ventricular  failure,  with  an  elevation  of 
trasnsmural right ventricular end diastolic pressure. (Rich et al 2005).
Pericardial Diseases:
            Pericardial diseases like tuberculosis, CRP and malignant 
involvement may also cause congestive heart failure.
Nutritional Causes:
            Vitamin deficiency like wet beriberi, anaemia and deficiency of 
hematopoetic factors leading to heart failure, continue to produce a problem especially 
in developing countries like India.        
PATHOPHYSIOLOGY:
           Heart  failure  is  the  multisystem disorder  which  is  characterized  by  the 
abnormalities  of  cardiac,  skeletal  muscle  and  renal  function  with  stimulation  of  the 
sympathetic nervous system and a complex pattern of neurohormonal changes.
Myocardial Systolic Dysfunction:
         The primary abnormality in non valvular HF is an impairment in the 
left ventricular (LV) function leading to fall in cardiac output. This fall in 
cardiac output leads to activation of several neurohormonal compensatory 
mechanisms aimed at improving the mechanical environment of heart. 
Activation of sympathetic system tries to maintain cardiac output with increase in heart 
rate, increases myocardial contractility and peripheral 
vasoconstriction. Activation of Renin-Angiotensin-Aldosterone system 
(RAAS) results in vasoconstriction and increase in blood volume with salt and water 
retention. Concentration of vasopressin and natriuretic peptides increase. Furthermore 
there may be progressive cardiac dilatation or alterations in cardiac structure or both 
(Borgeon, Burnett, 1997).
Renin – Angiotensin – Aldesterone system (RAAS)
           Simulation of RAAS leads to increased concentration of Renin, 
Angiotensin II (AT II) and Aldosterone. AT II is a potent vasoconstrictor of renal and 
systemic circulation where it  stimulates release of  Nor  Adrenaline from sympathetic 
nerve terminals, which inhibits vagal tone and promotes release of Aldosterone. This 
leads to sodium and water retention, in addition, AT – II has an important effects on 
cardiac myocytes and may contribute to endothelial dysfunction. (Francis et al, 1990)
Sympathetic Nervous System:
          Sympathetic nervous system is activated in HF via low and high 
pressure baroreceptors as an early compensatory mechanism which provides inotropic 
support and maintain cardiac output.  In long term, the ability of the myocardium to 
respond to chronic high concentration of catecholamines is activated by down regulation 
of   ß-receptors.  This  may  be  associated  with  baroreceptor  dysfunction  and  further 
increase in sympathetic activity (Schoffer et al, 1987).
Natriuretic Peptides:
         There are three natriuretic peptides of similar structure and these exert a wide  
range of effects on heart, kidneys and cardio vascular system. 
         Atrial natriuretic peptide (ANP) is released from atria in response to stretch,  
leading to natriuresis and vasodilatation. In humans, Brain 
natriuretic peptide (BNP) is also released from heart and its actions are similar to those 
of ANP. C- type natriuretic peptide is limited to vascular 
endothelium and CNS and has only limited effects on natriuresis and 
vasodilatation. (Van Chang et al, 2001 and Moe et al, 1993)
Vasopressin:
               Vasopressin concentration is also increased in severe chronic HF. High 
concentration of  the  hormone are  particularly  common in  patients  receiving diuretic 
treatment and this may contribute to development of  hyponatremia (Francis et al, 1990 
and Goldsmith, 1986).
Endothelin:
              Secreted by vascular endothelial cells, is a potent vasoconstrictor on  renal 
vasculature. Its concentration is also correlated with indices of 
severity  such  as  pulmonary  capillary  wedge  pressure  (PCWP)  and  need  for 
hospitalisation and death (Tsutamatoet al, 1995).
Patterns of Neurohormonal activation and prognosis
Asymptomatic left ventricular dysfunction:
             Plasma noradrenaline concentration increases early in development of left  
ventricular dysfunction and plasma renin activity usually increases in patients receiving 
diuretic  treatment.  Nor  adrenaline  concentration  in  patients  with  asymptomatic  LV 
dysfunction is a strong and independent predictor of development of symptomatic HF 
and long term morality.
            In severe untreated chronic HF, concentrations of renin, AT – II, 
Aldosterone, nor adrenaline and ANP are all increased. Plasma levels correlate with both 
the severity of HF and the long term prognosis. Patients with chronic HF and increased 
plasma nor adrenaline concentration do also have a worse prognosis (Esler, 1997).
Diastolic dysfunction:
           Diastolic dysfunction refers to clinical syndrome of HF with 
preserved Left Ventricle Ejection Fraction (EF – 0.4 or more) in the absence of major 
valvular disease. In diastolic HF, LV cavity is stiff due to increased LV mass. It relaxes 
slowly in early diastole and offers greater resistance to filling in late diastole so that 
diastolic pressure is increased. The low cardiac output manifests as fatigue while the 
increase in end diastolic pressure is transmitted backwards through valve less pulmonary 
veins to pulmonary capillaries resulting in exertional dyspnea (Vasa Levy, 2000).
              Mechanisms contributing to abnormal LV diastolic properties 
include stiff arteries, hypertension, ischemia, Diabetes and intrinsic 
myocardial changes with or without associated hypertrophy (Kitzman et al, 2002). The 
prognosis of diastolic HF is generally better than that of systolic Heart failure.
              Diastolic Heart failure is common in clinical practice. The 
Diagnosis of diastolic HF may be considered in patients with HF who have normal LV 
EF (0.4 or more) (Ibrahim, 2003).
Myocardial Dysfunction due to Remodeling, Hibernation and Stunning:
            After extensive myocardial infarction, cardiac contractility is 
frequently impaired and neurohormonal activation leads to regional 
eccentric and concentric hypertrophy of Non-infarcted segment with 
expansion of infarct zone. This is known as Ventricular Remodeling. 
Particular risk factors for this development of progressive ventricular 
dilatation after  an  MI  include  large infarcts,  anterior  infarctions,  occlusion of  artery 
related to infarction and hypertension. 
            Myocardial dysfunction may also occur in response to stunning 
which describes delayed recovery of myocardial function despite restoration of coronary 
blood flow in the absence of  irreversible  damage.  This  is  in  contrast  to  hibernating 
myocardium  which  describes  persistent  myocardial  dysfunction  due  to  reduced 
perfusion  although cardiac  myocytes  remain  viable  and myocardial  contraction  may 
improve with revascularization (Rahimtoola, 1989).
TYPES OF HEART FAILURE
Forward Failure:
It is defined as the inability of the heart to maintain effective stroke 
volume to meet the metabolic demands of the body.
Backward Failure:
              Small transient inequality between the two ventricles resulting in 
acute pulmonary edema.
Right sided heart failure:
               Due to stagnation of blood in the right side of the heart and
right heart failure signs develop.
Left sided heart failure:
               Due to poor LV contractile function in aortic stenosis or massive MI where the 
signs of left sided heart failure develops.
Acute heart failure Vs chronic heart failure:
               The clinical manifestations of HF depends mainly on the rate at 
which the syndrome develops and specifically whether sufficient time has 
elapsed for compensatory mechanisms to become operative and for fluid to accumulate 
in the interstitial space.
Low output Vs high output failure: 
               Heart failure in low cardiac output at rest or in milder cases during exertion  
characterizes most forms of cardiovascular diseases.
               High output heart  failure occurs in variety of high output states like  
thyrotoxicosis, Paget’s disease, AV fistulas anaemia and beriberi. (Stevenson 1989).
Systolic Vs diastolic HF:
               Implicit in the physiological definition of heart failure (inability to pump an  
adequate volume of blood and or to do so only from an abnormally elevated filling 
pressure)  is  that  heart  failure  can  be  caused  by  an  abnormality  in  systolic  function 
leading to  a  defect  in  expulsion of  blood leading to  systolic  heart  failure  or  by  an 
abnormality  in  diastolic  function  leading  to  a  defect  in  ventricular  filling  (diastolic 
failure). This may be due to slowed or incomplete ventricular relaxation, which may be 
transient  as  occurs  in  ischaemia,  or  sustained,  as  occurs  in  concentric  myocardial 
hypertrophy  or  restrictive  cardiomyopathy  secondary  to  infiltrative  conditions  like 
amyloidosis.
         The principal clinical manifestations of systolic failure result from 
an inadequate cardiac output and secondary salt  and water retention – forward heart 
failure (Gaasch 1994).
       Whereas the major consequence of diastolic HF is related to the 
elevation of ventricular filling pressure upstream to the ventricular cavity, 
causing pulmonary and systemic congestion (backward failure). (Vasan 
1995)
Clinical features and complications:
               Patients with HF present with a variety of symptoms, most of 
which are nonspecific. The common symptoms of congestive HF include 
fatigue, dyspnoea, pedal edema and exercise intolerance or symptoms that relate to the 
underlying cause.
Symptoms and signs in heart failure:
Symptoms
              Dyspnoea     
              Orthopnoea
              Palpitation
              Chest pain
              Reduced exercise tolerance, lethargy, fatigue
              Nocturnal cough
              Wheeze
              Ankle swelling
              Anorexia
Signs
            Cachexia and muscular wasting
             Tachycardia
             Pulsus alternans
             Increased JVP
             Displaced apex beat
             RV heave 
             Crepitations or wheeze
             3rd  heart sound
             Oedema
             Hepatomegaly, ascites
Symptoms:
Dyspnoea:
            Exertional breathlessness is the frequent presenting symptom in heart failure, 
although it  is  a  common symptom in patients  with pulmonary disease.  Dyspnoea  is 
therefore moderately sensitive but poorly specific for the presence of HF.
NYHA Classification of dyspnea:
Class I – no limitation of physical activity. ordinary physical activity does not cause 
undue symptoms.
Class II – slight limitation of physical activity. ordinary physical activity causes undue 
fatigue, dyspnea or palpitation.
Class III – moderate limitation of physical activity. less than ordinary activity causes 
symptoms.
Class IV – Severe restriction of  physical  activity.  unable  to  perform to any activity 
without symptoms.
Orthopnea:
Orthopnea is a more specific symptom. PND results from increased 
LV filling pressure and therefore has a greater sensitivity and predictive 
value (Maning 1995).
Fatigue and Lethargy
             Fatigue and Lethargy in CHF are due to impaired muscle blood flow and poor 
tissue perfusion. 
Oedema
            Swelling of ankles and feet is another common presenting feature. 
Heart failure may manifest as oedema, right hypochondrial pain (liver 
congestion) and loss of appetite (due to bowel congestion). An increase in 
weight may be associated with fluid retention although cardiac cachexia and 
weight loss are important markers of disease severity. (Milne 1985)
Physical Signs          
           Physical examination has serious limitations as many patients 
particularly those with less severe heart failure, have few abnormal signs. In addition 
some physical signs are difficult to interpret, and if present, may occasionally be related 
to diseases other than HF.
             Oedema and  tachycardia, for example are too intensive to have any useful 
predictive  value  and  although  pulmonary  crepitations  may  have  a  high  diagnostic 
specificity. Increased JVP has a high specificity in 
diagnosing HF in patients who are known to have cardiac disease.
             Displaced apex beat in patients with myocardial infraction and 3rd 
heart sound have a relatively high specificity.
Framingham Criteria for Diagnosis of Congestive Heart Failure:
Major Criteria
1) Paroxysmal nocturnal dyspnea
2) Neck vein distension
3) Rales
4) Cardiomegaly
5) Acute pulmonary edema
6) S3 gallop
7) Increased Venous Pressure (>16cm H2O)
8) Positive Hepatojugular reflux
Minor Criteria:
1) Extremity edema
2) Night Cough
3) Dyspnea on exertion
4) Hepatomegaly
5) Pleural effusion
6) Vital capacity reduced by one-third from normal
7) Tachycardia (≥ 120 bpm)
Major or Minor:
            Weight loss ≥ 4.5 kg over 5 days of treatment
                       To establish a clinical diagnosis of congestive heart failure by these  
criteria at least one major and two minor criteria are required.
AIM and OBJECTIVES
1) To study about the etiological profile of congestive heart failure.
2) To study about the clinical features of congestive heart failure.
3) To study about the Echocardiographic features of  congestive heart failure
MATERIALS and METHODS
Place              :    Department of Medicine
Design            :   Observational Study
Period             :   August 2007 to August 2008
Sample Size    :   100 Patients
Collaborating  :    Cardiology 
Departments
Inclusion Criteria
1) All  patients  above 12 years  of  age with  clinical  evidence  of  congestive  heart 
failure.
2) Patients of Both sexes.
Exclusion Criteria
1) Patients less than 12 years of age
2) Hemodynamically unstable patients 
3) Pregnant women
4) Patients with Cor Pulmonale
METHODS:
1. Thorough history.
2. Complete physical examination.
3. Chest X-ray.
4. ECG.
5. Complete Blood Count
6. Renal Function Tests.
7. Echo cardiography
Definitions used for the study
1) Dyspnea:
                      Subjective awareness of the sensation of breathing
2) Orthopnea:
                      Dyspnea on assuming recumbency.
3) Angina:                   
                      Retrosternal chest discomfort due to myocardial ischemia.
4) Palpitation:
Abnormal and uncomfortable awareness of one own heart beat.
Diabetes:
          American diabetes association criteria for the diagnosis of 
diabetes mellitus.
1. Symptoms of diabetes plus blood glucose concentration ≥ 200 mg/dl or
2. Fasting plasma glucose ≥ 126 mg/dl or
3. Two hour plasma glucose ≥ 200 mg/dl during an oral glucose 
     tolerance test.
Hypertension: 
          Clinical blood pressure of > 140/90 mm Hg confirmed on two 
separate occasions. (JNC > criteria)
Ischemic Heart Disease:
           IHD and CAD is typically defined as a > 50% stenosis of any 
epicardial coronary artery.
            Manifestations of CAD include stable angina, acute coronary 
Syndrome (ACS), congestive heart failure, sudden cardiac death and silent ischemia.
MI – Regional wall Motion abnormalities in Transthoracic Echo              
cardiography
                            Hypokinesia     
                            Akinesia
                            Dyskinesia
Rheumatic Heart Disease:                
             Evidence of valvular involvement in the form of thickening, fibrosis or 
calcification.
Ejection Fraction:
             Depressed ejection fraction < 40%
             Normal ejection fraction > 50%
Dilated Cardiomyopathy:
             Demonstration of global hypokinesia of left ventricle without regional wall 
motion abnormalities.
 
OBSERVATIONS & DATA ANALYSIS
Total Number of Patients – 100
       Male         -       67
                                                  Female      -       33
Mean Age of Patients     = 50 yrs
TABLE - 1
AGE(Years) MALE FEMALE TOTAL (n=100)
12 - 20 4 4 8
21 - 30 5 2 7
31 - 40 5 4 9
41 - 50 12 9 21
51 - 60 21 9 30
61 - 70 15 3 18
> 70 6 1 7
AGE & SEX DISTRIBUTION
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TABLE - 2
PRESENTING FEATURES
Dyspnea class Male Female Total(n=100) 
Class I 0 0 0
Class II 2 0 2
Class III 28 11 39
Class IV 37 22 59
           Dyspnea is the most common presenting symptom. 100% of patients had 
dyspnea. Majority (59%) of patients were in Class IV failure.
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TABLE - 3
SYMPTOM COMPLEX
Symptoms Males Females Total(n=100)
Orthopnea 63(94%) 32(97%) 95
PND 25(37%) 13(39%) 38
Fatigue 59(88%) 31(94%) 90
Pedal Edema 54(80%) 24(72%) 78
Angina 20(30%) 9(27%) 29
Palpitation 22(33%) 21(63%) 43
Night Cough 45(67%) 17(51%) 62
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Next to dyspnea, Orthopnea is the most common symptom, 
followed by fatiguability and pedal edema. Significant percentage of females had 
palpitation compared to males.
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TABLE - 4
MAJOR RISK FACTORS
RISK 
FACTORS
Male Female Total
Diabetes 30 6 36
Hypertension 35 12 47
RHD 9 17 26
Cardiomyopath
y
1 2 3
Others 0 0 0
                                     Already existing structural heart disease is the major risk factor 
for CHF. 75% of patients had a history of heart disease in the past. Ischemic heart 
disease is the most common structural heart disease.
MAJOR RISK FACTORS
30
35
40
9
1
0
6
12
6
17
2
0
36
47
46
26
3
0
0
5
10
15
20
25
30
35
40
45
50
Diabetes Hypertension IHD RHD Cardiomyopathy Others
RISK FACTORS
Male
Female
Total
 
TABLE - 5
SIGNS
SIGNS Male Female Total
Pulse Rate 51 22 73
JVP > 16 cm 60 29 89
Positive HJR 8 4 12
Pedal Edema 57 28 85
S3 gallop 39 14 53
Pulmonary Rales 67 33 100
Pleural Effusion 19 1 20
Hepato megaly 31 15 46
                                  The most common sign in CHF is Basal pulmonary 
rales followed by elevated JVP (89%) and pedal edema (85%)
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TABLE - 6
CHEST     X - ray
Sign Total
Cardio megaly 91
Pleural effusion 17
                                  Cardiomegaly is a sensitive sign of CHF occurring in 
91% of patients.                      
CHEST X-ray
91
17
Cardio megaly
pleural effusion
TABLE - 7
ECG
Sign Total
Evidence of old MI 36
Ischemic changes 43
Atrial fibrillation 28
Left – Bundle branch block 17
Right Bundle branch block 15
Bifascicular block 9
Left ventricular 
hypertrophy
7
                           
  
          Electrocardiography evidence of IHD is found in 43% of patients. Atrial 
fibrillation is the only arrhythmia which had been documented apart from sinus 
tachycardia.
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TABLE -7
ECHOCARDIOGRAPHIC FINDINGS
Ischemic Heart Disease
Sign Total ( n - 52)
Hypokinesia  37 (71%)
Akinesia 12 (23%)
Dyskinesia 3 (6%)
Ejection Fraction ≤ 40% 38 (73%)
Diastolic Dysfunction 13 (25%)
                         Depressed Ejection fraction is found in 73% of patients of 
IHD, while 25% of patients had Diastolic dysfunction.
ISCHEMIC HEART DISEASE
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TABLE - 8
Rheumatic Heart Disease
Lesion Total (n – 24)
Mitral Stenosis (MS) only 4 (16%)
Mitral regurgitation (MR) only 3 (12%)
Combined MS & MR 11 (46%)
Combined MS & Aortic
regurgitation (AR)
2 (8%)
Combined AR + MR 4 (16%)
      
           Among the Rheumatic Heart diseases, combined MS & MR accounted for a large 
proportion (46%) of cases of CHF.

TABLE – 9
Hypertensive Heart Disease
Sign Total (n - 11)
Left Ventricular 
hypertrophy
11
Left atrial enlargement 2
Diastolic dysfunction 11
Hypertensive Heart Disease
11
2
11
Left ventricular
hypertrophy 
left atrial enlargement
Diastolic dysfunction
TABLE -10
Dilated Cardiomyopathy
Sign Total (n – 9)
Ejection Fraction 
<  40 %
8 (88%)
Mitral regurgitation 4 (44%)
Dilated Cardiomyopathy
8(88%)
4(44%)
Ejection fraction
Mitral regurgitation
TABLE -11
ETIOLOGICAL PROFILE
Diagnosis Male (n - 67) Female (n - 33) Total (n - 100)
Ischemic Heart 
disease
41 (61%) 11 (33%) 52
Hypertensive Heart 
disease
8 (12%) 3 (9%) 11
Rheumatic Heart 
disease
9 (13%) 15 (45%) 24
Dilated 
Cardiomyopathy
6 (9%) 3 (9%) 9
Anemia 3 (4%) 1 (3%) 4
                
                   Ischemic Heart disease accounts for a majority (52%) of cases of  CHF. 
Rheumatic heart disease is the most common cause of Heart failure in females followed 
by Ischemic Heart disease.
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TABLE-12
Age and Heart Failure
Diagnosis Mean Age (yrs) Total
Ischemic Heart disease 59.2 52
Rheumatic Heart 
disease
32.5 24
Hypertensive Heart 
disease
52.1 11
Dilated 
Cardiomyopathy
45.1 9
Anemia 32.7 4
          
           The mean Age of patients with CHF due to IHD was 59.2. The Mean age was low 
(32.5 yrs) for Rheumatic heart diseases compared to others.
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DISCUSSION
           The total number of patients analyzed were 100, out of which 67% 
were male patients. The Mean Age of patients found in the study was 50 
years. Patients between the age group of 51 – 60 years accounted for a large proportion 
of cases.       
          The most common presenting complaint is dyspnea. Majority (59%) of patients  
with dyspnea were in class IV failure. This proportion is much higher compared to Euro 
heart failure survey where only 34% of patients had class IV failure.         
         Orthopnea is the second most common symptom constituting 95% of patients 
followed by Fatigue (90%) and Pedal Edema (78%).
RISK FACTORS:
        Ischemic Heart disease is the most common structural heart disease 
predisposing to the development of chronic congestive Heart failure 
followed by hypertension and Diabetes. This finding correlate well with 
Framingham Heart study. Rheumatic heart disease accounts for a significant proportion 
of heart failure in this study as opposed to the western data.
SIGNS:
       Basal pulmonary rales is the most consistent sign associated with CHF followed by 
elevation of JVP (89%) and Pedal Edema (85%).    
       Chest skiagram revealed enlarged cardiac shadow in a majority of patients. As such 
chest X-ray can be considered as a sensitive test for the 
initial diagnosis of CHF. Electro cardiographic evidence of Ischemic Heart disease is 
found in 43% of patients.
AETIOLOGY:
     The most common cause of CHF in this study was Ischemic heart disease (52%) 
followed by Rheumatic heart disease (24%) and hypertensive heart disease. This study 
shows a higher prevalence of Rheumatic heart disease as a cause of CHF compared to 
western data. Combined valvular lesions are associated with increased risk of congestive 
heart failure.
ECHO CARDIOGRAPHY:
       Among patients with non - valvular heart disease 61% of 
patients had depressed ejection fraction (≤ 40%). Among patients  with IHD 73% of 
patients had depressed ejection fraction.  Diastolic  dysfunction is present  in 24 % of 
patients.
AGE AND CHF:     
      The Mean Age of patients with CHF due to IHD was 59.2 years whereas RHD leads 
to  CHF  at  an  earlier  age  (32.5  years).  The  presence  of  diastolic  dysfunction  in 
Hypertensive Heart disease leads to CHF at an earlier age (52.1 years) compared to 
Ischemic heart disease.
CONCLUSION
1. In this study 67% of patients were males and 33% of patients    
    were females. The mean age of patients was 50 years.
2. The highest number of patients with CHF was in the age group 
     of 51 – 60 years.
3. Ischemic heart disease was the most common risk factor for the 
    development of chronic CHF.
4. Dyspnea was the most common presenting symptom and 
    majority of them (59%) were in class IV failure.
5. Basal pulmonary rales was the most common clinical sign of  
    CHF followed by elevated JVP and pedal edema.
6. Chest X-ray showed evidence of cardio megaly in majority
    (91%) of patients.
7. Atrial fibrillation was the only arrhythmia documented apart  
    from sinus tachycardia.
8. The most common cause of congestive Heart failure is Ischemic 
    heart disease (52%) followed by rheumatic Heart disease (24%) 
    and Hypertension (11%).
9. Among the patients with non-valvular heart disease, 61% had 
    depressed ejection fraction (≤ 40%) while 24 % had Diastolic 
    dysfunction
10. Rheumatic heart disease accounted for a majority of cases of
      CHF, relatively at an earlier age (Mean 32.5 years) compared
      to IHD (Mean 59.2 years).
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PROFORMA
         HEART  FAILURE
Name :                                                             I.P.NO :
Age :                                                                Sex :
Occupation :                                                    Income :
Residence :
Present Illness :
1.Breathlessness                         Yes / No
    Class                 I     II      III         IV
2.Orthopnea                                Yes / No
3.PND                                         Yes / No
4.Night Cough                             Yes / No
5.Chest Pain                                Yes / No
6.Palpitation                                Yes / No
7.Syncope                                   Yes / No
8.Pedal Edema                            Yes / No
9.Oliguria                                    Yes / No
10.Nocturia                                 Yes / No
Past History :
1.Diabetes                                   Yes / No
2.Hypertension                            Yes / No
3.IHD                                          Yes / No
4.Cardiomyopathy                       Yes / No
5.Congenital Heart
     Disease                                   Yes / No
6.RHD                                         Yes / No
7.Thyroid Disorders                     Yes / No
8.Anemia                                     Yes / No
9.CKD                                          Yes / No
10.Others                                      Yes / No
Personal History
1.Smoking                                     Yes / No
2.Alcoholism                                 Yes / No
3.Drug Abuse                                 Yes / No
4.STI                                              Yes / No
Family History 
1.Diabetes                                      Yes / No
2.Hypertension                               Yes / No
3.Heart Disease                               Yes / No
Examination :
1.Consciousness                        Normal / Altered 
                                           
2.Pallor                                            Yes / No
3.Dyspnea                                       Yes / No
3.Cyanosis                                       Yes / No
4.Clubbing                                       Yes / No
5.Extremity Edema                          Yes / No
6.JVP                                               Raised / Not Raised
7.Blood Pressure :                                       Temperature :               Weight : 
8.Pulse :
9.Respiratory Rate :
Cardio-Vascular System :
1.Heart Sounds
2.Murmur
3.S 3
Respiratory System:
1.Rales                                            Yes / No
2.Pleural Effusion                           Yes / No
Abdomen:
1.Hepatomegaly                               Yes / No
CNS :
Investigations :
1.Hemogram:
    Hb 
    Tc
    Dc
    ESR
2. Blood:
     Sugar
     Urea
     Creatinine
     Na             K             Cl                 Hco3
3.Chest X-Ray:                                                              
4.ECG :
5.Echocardiography:
Final Diagnosis :
         ABBREVIATIONS
ACE – Angiotensin Converting Enzyme
ANM-anemia
AS – Aortis Stenosis
AR – Aortic Regurgitation
BP –Blood Pressure
CHF – Congestive Heart Failure
CM – Cardiomegaly
DC – differential count
CXR – Chest X-Ray
DM – Diabetes Mellitus
DCMP – Dilated Cardiomyopathy
ESR – erythrocyte sedimentation rate
EF – Ejection Fraction
Hb – Hemoglobin
HT – Hypertension
HJR – Hepatojugular Reflex
HHD – Hypertensive Heart Disease
IHD – Ischemic Heart Disease
JVP – Jugular Venous Pressure
LV – Left Ventricle
MS – Mitral Stenosis
MR – Mitral Regurgitation
PR – Pulse Rate
PF – Pleural Effusion
RHD – Rheumatic Heart Disease
RV – Right Ventricle
TC – total white blood cell count
MASTER CHART
1 – Yes
2 - No

